Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has be...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagnasco, Diego, Canevari, Rikki Frank, Del Giacco, Stefano, Ferrucci, Silvia, Pigatto, Paolo, Castelnuovo, Paolo, Marseglia, Gian Luigi, Yalcin, Arzu Didem, Pelaia, Girolamo, Canonica, Giorgio Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703799/
https://www.ncbi.nlm.nih.gov/pubmed/36474912
http://dx.doi.org/10.1016/j.waojou.2022.100721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703799/
https://www.ncbi.nlm.nih.gov/pubmed/36474912
http://dx.doi.org/10.1016/j.waojou.2022.100721

Ejemplares similares